Other approaches (GIP/CB1/amylin more on these later and in follow on notes), might try to go head-to-head with GLP-1, but are likely to disappoint as, and will ultimately settle for being combinations or acting as niche treatments for GLP-1 non-responders or population sub-segments
Hims avoided infringing on the patents protecting the SNAC technology by using liposomal technology, or fatty bubbles, to encase the drugs
Initially it may be a few times a week
[PUBMED Abstract] Subbiah V, Hu MI, Wirth LJ, et al.: Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
This recognition occurs during infections caused by bacteria, viruses, or fungi, enabling a rapid inflammatory response before the pathogen inflicts significant harm (39)